Isotretinoin therapy: A retrospective cohort analysis of completion rates and factors associated with nonadherence
To the Editor: Acne medication nonadherence remains a primary cause of treatment failure and is a major challenge dermatologists encounter in treating acne patients. [1] [2] [3] Adherence to isotretinoin therapy is particularly important, given its cumulative dose-dependent mechanism for inducing remission, yet there is limited literature on this topic. 3, 4 Reported adherence rates range 54%-96% for the first course of isotretinoin therapy. 1, 2, 5 Our aim was to examine isotretinoin treatment compliance and explore common reasons for nonadherence.
We performed a retrospective chart review of 544 patients prescribed isotretinoin at the University of California Los Angeles Dermatology Clinic during 2010-2015. Institutional Review Board approval was obtained. Exclusion criteria included incomplete medical records or access restriction, chronic low-dose or alternate therapy, and noneacne diagnosis. Adherence was defined as reaching a cumulative dose of 120-150 mg/kg or completion of therapy as determined by the treating clinician. 4 On the basis of this definition, patients were divided into 1 of 6 major categories: completed, likely completed, lost to follow-up (LTFU), patientstopped, physician-stopped, or never started.
Overall, 458 patients (50.4% female) were included in this analysis. Of these, 53.9% completed therapy, 18.3% likely completed therapy, 15.5% were lost to follow-up, 5.9% stopped CAT, Clinical activities tool; CI, confidence interval; IQR, interquartile range; OBME, outcomes-based medical education. *Adjused for beginning-of-clerkship student self-assessment survey scores. y Mean scores are calculated from a 1-10epoint scale, from strongly disagree to strongly agree, with 5 being neutral. z Agreeing indicates a score $6.
x Average evaluation score is the mean of 6 individual clerkship evaluations. jj P value of .271 from Wilcoxon rank-sum test.
due to physician orders, 4.2% self-discontinued, and 3.1% never started therapy. After excluding the never started and physician-stopped groups from the total study population, we found an overall adherence rate of 78.6%, which counted the completed and likely completed groups as adherent and the LTFU and patient-stopped groups as nonadherent.
When comparing adherent versus nonadherent patients, we found no statistically significant difference in age, sex, or previous isotretinoin course status. However, when comparing LTFU versus adherent patients, we found that significantly more LTFU patients were male and had $1 previous course of isotretinoin (P ¼ .03 and P ¼ .04, respectively) ( Table I) . Most nonadherent patients did not complete therapy simply by failing to return to the clinic for follow-up appointments; over a third of these patients failed to complete the first follow-up appointment after initiating therapy (Fig 1) .
Clinical and logistical factors contributed to medication nonadherence. The most commonly cited reason for both physician and selfdiscontinuation was mood changes. Other reasons for self-discontinuation included travel/moving and unwillingness to reduce alcohol intake. The most commonly documented reason for not initiating therapy was iPLEDGE difficulties.
Of the 133 female patients who completed therapy, only 61.7% had a documented 30-day post-therapy pregnancy test. Age and prior treatment status did not have a statistically significant effect on obtaining last pregnancy test.
The strengths of this study are the large number of patients prescribed only isotretinoin therapy and characterization and evaluation of different subgroups of nonadherent patients. The study's retrospective nature limited our ability to capture the reason patients were lost to follow-up. On the basis of our findings, we suggest that improved patient screening and education for patients who might be unable to comply with iPLEDGE requirements and close attention to increasing first-month follow-up rates (via telephone and message reminders) might be critical to increasing successful initiation and completion of isotretinoin therapy. Future studies could evaluate adherence rates after implementation of these interventions. Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis To the Editor: Urticaria is an allergic disease that can be classified into acute and chronic forms. Autoimmune responses are believed to contribute to the pathogenesis of chronic urticaria. 1 A vitamin D deficiency is associated with various autoimmune and allergic diseases, such as atopic dermatitis. 2 We attempted to meta-analyze current studies to elucidate the relationship between vitamin D deficiency and different types of urticaria in patients of different ages.
On November 30, 2017, we searched databases for studies comparing the prevalence of vitamin D deficiency or vitamin D levels between patients with urticaria and controls. Odds ratio (OR) and standardized mean difference (SMD) were calculated using a random effects model.
Fourteen studies with 1655 patients with urticaria were included for analysis. The pooled prevalence of vitamin D deficiency was significantly higher in patients with urticaria than in the control group (OR 4.456, 95% confidence interval [CI] 2.261-8.782; Fig 1) . Subgroup analysis revealed that the prevalence of vitamin D deficiency was significantly higher in patients with chronic urticaria than in the control group (OR 5.723, 95% CI 2.617-12.516), but a similar difference was not observed in patients with acute urticaria (OR 3.031, 95% CI 0.706-13.022).
Random effects pooling of the 11 studies providing vitamin D levels revealed that patients with urticaria had a significantly lower level of vitamin D than the control group (SMD À1.211, 95% CI À1.832 to À0.591; Fig 2) . Subgroup analysis indicated that the vitamin D level was significantly lower in patients with chronic urticaria than in the control group (SMD À1.067, 95% CI À1.865 to À0.268); vitamin D level was lower in patients with acute urticaria but the difference was not significant (SMD À1.009, 95% CI À2.314 to 0.296). The vitamin D level was significantly lower in adult patients with urticaria than the control group (SMD À1.741, 95% CI À3.472 to À0.010), but was not significantly lower in pediatric patients with urticaria than the control group (SMD À1.151, 95% CI À3.725 to 1.424).
The vitamin D pathway influences the allergic and autoimmune responses. 25-Hydroxyvitamin D3 is converted by mast cells into metabolites that repress IgE-mediated mast cell activation. 3 Vitamin D enhances T regulatory cells, which contributes to the suppression of proallergic and autoimmune
